Company Description
BIOLASE INC (BIOLQ) is associated with BIOLASE, a company described as the world's leading innovator in dental laser technology. According to company statements, BIOLASE focuses on manufacturing high-performance dental laser systems that advance dentistry and improve patient experiences, with a legacy spanning more than three decades.
BIOLASE operates in the healthcare sector with a focus on medical devices, particularly dental lasers used in periodontal, implant, and other dental procedures. Its technology is presented as a foundation for minimally invasive dentistry, emphasizing patient comfort and clinical outcomes. Company materials highlight that BIOLASE has played a role in the evolution of laser-based dental treatments over many years.
Business focus and technology
BIOLASE describes itself as a global leader in dental laser technology, with systems designed for all-tissue applications in dentistry. The company highlights Er,Cr:YSGG laser technology as a core platform, used in periodontal and implant care and in protocols for periodontitis treatment. BIOLASE states that its systems are intended to support predictable clinical results, efficiency for clinicians, and improved patient comfort.
In company communications, BIOLASE emphasizes minimally invasive treatment pathways and the use of YSGG laser technology in procedures such as periodontal pocket management, bacterial decontamination, and osseous contouring, as described in its educational and conference materials. These uses are framed as part of modern periodontics and implant dentistry.
Corporate developments and ownership
BIOLASE has reported that it was founded over 35 years ago and has been active in dental laser innovation for multiple decades. The company has publicly stated that it introduced dental laser systems under the Waterlase name, which it associates with improvements in patient comfort and clinical outcomes.
According to a company announcement, BIOLASE entered a new phase after its acquisition by MegaGen Implant. BIOLASE characterizes this change in ownership as a transition that supports continued operation of the business, with an emphasis on renewed focus on innovation, quality, and customer service. The company describes this as a revitalization under new leadership, while maintaining its focus on dental laser technology.
Products and clinical applications
In public materials, BIOLASE refers to high-performance dental laser systems and all-tissue laser platforms. It highlights Er,Cr:YSGG-based systems and Waterlase-branded devices in the context of periodontal and implant care, periodontitis treatment protocols, and other minimally invasive dental procedures. The company associates these systems with goals such as reduced bleeding and swelling, less postoperative discomfort, and faster procedures compared with certain traditional surgical techniques, based on referenced clinical research.
BIOLASE also emphasizes education and clinical training as part of its presence at professional meetings. Company communications describe lectures, live demonstrations, and hands-on sessions that present YSGG laser protocols, clinical advantages in periodontal and implant procedures, and approaches to integrating all-tissue laser technology into dental practices.
Industry role
Within the broader healthcare and medical devices space, BIOLASE positions itself specifically within dental devices and laser dentistry. Its communications focus on minimally invasive dentistry, periodontal and implant care, and the use of laser systems as tools for modern dental practice. Over its multi-decade history, as described by the company, BIOLASE has aimed to define and expand the role of laser technology in clinical dentistry.
FAQs about BIOLASE (BIOLQ)
Stock Performance
Latest News
SEC Filings
No SEC filings available for Biolase.
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Biolase (BIOLQ) currently stands at 13.0 thousand shares, representing 0.0% of the float. Over the past 12 months, short interest has increased by 42.4%. This relatively low short interest suggests limited bearish sentiment. With 1000.0 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for Biolase (BIOLQ) currently stands at 1000.0 days, up 725.1% from the previous period. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has increased 99899% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 1000.0 days.